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.2011.11.0Abstract Stability-indicating high-performance thin-layer chromatographic (HPTLC) method for
the analysis of ropinirole HCl was developed and validated as per the ICH guidelines. The method
employed the mobile phase and toluene-ethyl acetate-6 M ammonia solution (5:6:0.5, v/v/v) was
optimized with the help of a design expert. Densitometric analysis of ropinirole HCl was carried
out in the absorbance mode at 250 and 254 nm. Compact spots for ropinirole HCl were found
at Rf value of 0.58 ± 0.02. The linear regression analysis data for the calibration plots showed
R2 = 0.9989 ± 0.0053 with a concentration range of 100–3000 ng spot1. The method was vali-
dated for precision, accuracy, ruggedness, robustness, speciﬁcity, recovery, limit of detection
(LOD) and limit of quantitation (LOQ). The LOD and LOQ were 12.95 and 39.25 ng spot1 respec-
tively. Drug was subjected to acidic, alkaline, oxidative, dry heat, wet heat and photo degradation
stress. All the peaks of degradation products were well resolved from the standard drug peak with
signiﬁcant difference of Rf. The acidic and alkaline stress degradation kinetics of ropinirole, were
found to be in ﬁrst order, showing high stability (t1/2, 146.37 h
1; t0.9, 39.11 h
1) in the acidic
medium and low stability (t1/2, 97.67 h
1; t0.9, 14.87 h
1) in the alkaline environment.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.nt of Pharmaceutics, Faculty
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061. Introduction
Parkinson’s disease (PD) is one of the most common progres-
sive, neurodegenerative disorders primarily affecting dop-
aminegic neuronal systems, with impaired motor functions
(Nyholm, 2006). It is manifested by the ‘cardinal signs’ of bra-
dykinesia, rigidity of the extremities, resting tremor, and, later
in the disease, postural reﬂex impairment. Ropinirole hydro-
chloride, 4-[2-(dipropylamino) ethyl]-1,3-dihydro-2H-indole-ier B.V. All rights reserved.
NH
O
N
Figure 1 Chemical structure of ropinirole HCl.
94 G. Mustafa et al.2-one hydrochloride (Fig. 1), is a speciﬁc D2 and D3 receptor
non-ergoline dopamine agonist recently introduced, indicated
for the treatment of PD (Nyholm, 2006) and has been proven
to be effective in both monotherapy and in combination with
therapy for Parkinson’s disease (Kaye and Nicholls, 2000; Bo-
gan et al., 2006). It is being increasingly used as monotherapy
in the initial treatment of Parkinson’s disease rather than as
adjunct to levodopa (Standaert and Young, 2006). In addition,
ropinirole is also efﬁcacious in the management of advanced
Parkinson’s disease in patients experiencing motor complica-
tions after long-term levodopa therapy (Matheson and Spen-
cer, 2000).
High-performance liquid chromatography (HPLC) with
ultraviolet (Ramji et al., 1999), electrochemical (Swagzdis
et al., 1985), or mass spectrometric detection (Bhatt et al.,
2006) have been developed for the quantiﬁcation of ropinirole.
Thermospray LCMS and LCMS/MS have been used for the
analysis of ropinirole metabolites in urine samples (Beattie
and Blake, 1989). Separation and quantiﬁcation of ropinirole
HCl and some potential impurities have been attempted using
capillary liquid chromatography (Coufal et al., 1999) and by
HPLC with UV and diode-array detection (Sahasrabuddhey
et al., 2007; Zissis et al., 1997). However to our knowledge,
no information related to the stability-indicating high-perfor-
mance thin-layer chromatographic (HPTLC) determination
of ropinirole in pharmaceutical dosage forms has ever been
mentioned in the literature. There is need of simple analytical
methodology for the estimation of highly used ropinirole. An
ideal stability-indicating method shall quantify the drug per
se and also resolve its degradation products. The purpose of
the present study is to subject ropinirole to a variety of sug-
gested stress test conditions to establish inherent stability of
the drug and to develop the validated stability indicating
HPTLC assay. The mobile phase for the proposed method
was screened with the help of a trial version of design expert
software, Furthermore, the developed HPTLC method was
used to investigate the kinetics of acidic and alkaline stress
degradation processes by the quantiﬁcation of drug at different
temperature, to calculate the activation energy, degradation
rate constant, half-life and shelf life of ropinirole in the sub-
jected stress conditions.
Considering the above, a simple, precise and stability-indi-
cating HPTLC method for quantitative analysis of ropinirole
was developed, and the method was validated according to
the ICH guideline. The developed method can be used for
the in vitro and in vivo analysis of ropinirole HCl.2. Experimental
2.1. Chemicals and reagents
A sample of ropinirole HCl was obtained as a gift from Dr
Reddy’s Laboratories, Hyderabad, India. HPLC-grade
toluene, ethyl acetate, and aqueous ammonia were purchased
from E. Merck, Mumbai, India. Ropinirole tablets (Ropark,
Torrent Pharmaceuticals, Indrad, India) was purchased for the
analytical purpose. HPLC-grade water (LiChrosolv) from
E. Merck, Mumbai, India. All the other chemicals and reagents
used were of AR grade and purchased from E. Merck,
Mumbai, India.
2.2. HPTLC instrumentation and chromatographic conditions
A stock solution of ropinirole HCl (100 ng lL1, calculated as
free base) was prepared in HPLC water. Standard solution
prepared was used for the application of track, to get a concen-
tration range of 100–3000 ng spot1.
The prepared dilution of standards were spotted in the form
of bands of width 5 mm with a Camag microliter syringe on
pre-coated silica gel aluminium Plates 60F-254 (10 cm · 10 cm,
200 lm thickness, Merck, Darmstadt, Germany) using a
Linomat V (Camag, Muttenz, Switzerland) sample applicator.
The plates were prewashed by methanol and activated at 60 C
for 2.5 min prior to chromatography. Before the application of
the sample it was preﬁltered through a 0.22 lm Nylon ﬁlter. A
constant application rate of 150 nL s1 was employed and the
space between the two bands was 10 mm. The slit dimension
was kept at 5 mm · 0.45 mm and 20 mm s1 scanning speed
was employed. The mobile phase consisted of toluene-ethyl ace-
tate-6 M ammonia solution (5:6:0.5, v/v/v). Linear ascending
development was carried out in 10 cm · 10 cm twin-trough
glass chamber saturated with the mobile phase to a distance
of 80 mm. The optimized chamber saturation time for the mo-
bile phase was 15 min at room temperature (25 ± 2 C) and at
relative humidity of 55 ± 5%. Subsequent to the development,
TLC plates were dried in a current of air with the help of an
air-dryer. Densitometric scanning performed on Camag TLC
scanner III in the absorbance mode was tried at 250 and
254 nm to see if there were any differences in the absorptivity.
The source of radiation utilized was a deuterium lamp emitting
a continuous UV spectrum in the range of 200–300 nm.
Evaluation was done using linear regression analysis via
peak areas.
2.3. Software aided method optimization
Box-Behnken statistical screening design was used to optimize
the compositional parameters and to evaluate interaction
effects and quadratic effects of the mobile phase composition
on the retardation factor (Rf). Response surface methodolo-
gies, such as the Box-Behnken and Central Composite Design
(CCD), the model possible curvature in the response. A 3-fac-
torial, design used is suitable for exploring quadratic response
surfaces and constructing second order polynomial models
with Design Expert (Version 7.0.0.1, Trial Version). The
Box-Behnken design was speciﬁcally selected since it requires
fewer runs than a CCD in cases of three or four variables. A
Box-Behnken supported validation of stability-indicating high performance 95design matrix comprising of 17 experimental runs was
constructed. The non-linear computer generated quadratic
model is given as
Y ¼ b0  b1X1 þ b2X2  b3X3  b4X1X2  b5X1X3 þ b6X2X3
 b7X21 þ b8X22 þ b9X23
where Y is the measured response (Rf) associated with each fac-
tor level combinations; Toluene (X1), Ethyl acetate (X2) and
amount of Ammonia (X3) solution. The dependent and inde-
pendent variables selected are shown in Table 1 along with their
low, medium and high levels, which were selected based on the
results from preliminary experimentation. The concentration
range of Toluene (X1), Ethyl acetate (X2) and Ammonia (X3)
used to prepare the 17 analytical trial and the respective
observed responses are given in Table 2.
2.4. Calibration curve of ropinirole
A stock solution of ropinirole HCl was prepared in HPLC
water of 100 lg mL1. Different volumes of stock solution
ranging from 0.1, 0.2, 0.3, 0.4, 0.5, 0.8, 1.0, 1.5, 2.0 and
3 lL, were spotted on the TLC plate (10 cm · 10 cm) to obtain
concentrations of 100, 200, 300, 400, 500, 800, 1000, 1500, 2000
and 3000 ng spot1 of ropinirole respectively. Each concentra-
tion was spotted three times on the TLC plate. The data ofTable 1 Variables selected in Box-Behnken design.
Factor independent variables Levels used
Low (1) Medium (0) High (+1)
X1 = Toluene (v/v ratio) 3 6 9
X2 = Ethyl acetate (v/v ratio) 2.5 5.5 7.5
X3 = Ammonia (v/v ratio) 0.125 0.25 0.375
Dependant variables Constraints
0.23 6 Y 6 0.83
Table 2 Observed responses in Box-Behnken design for 17
analytical trials.
Run Independent variables Dependent variables,
i.e. retardation
factor (Y)
Toluene
(X1)
Ethyl
acetate (X2)
Ammonia
(X3)
1 6 9 0.10 0.67
2 6 2 0.40 0.21
3 6 9 0.40 0.68
4 6 5.5 0.25 0.38
5 3 5.5 0.40 0.54
6 9 5.5 0.40 0.26
7 3 2 0.25 0.31
8 6 2 0.10 0.23
9 6 5.5 0.25 0.39
10 3 9 0.25 0.78
11 6 5.5 0.25 0.38
12 9 2 0.25 0.068
13 3 5.5 0.10 0.54
14 6 5.5 0.25 0.37
15 9 9 0.25 0.49
16 9 5.5 0.10 0.267
17 6 5.5 0.25 0.368peak areas plotted against the corresponding concentrations
were treated by linear least-square regression analysis.
2.5. Method validation
The analytical method was validated for accuracy, precision,
limit of detection (LOD), limit of quantiﬁcation (LOQ), spec-
iﬁcity, robustness, and ruggedness, in accordance with ICH
guidelines.
2.5.1. Precision
Repeatability of sample application and measurement of peak
area were carried out using three replicates of the same concen-
tration (500 ng spot1 of ropinirole HCl). It showed very
low% RSD of peak area of ropinirole HCl. The intra and in-
ter-day variation for the determination of ropinirole HCl was
carried out at three different concentration levels of 250, 500
and 1000 ng spot1.
2.5.2. Limits of detection (LOD) and quantiﬁcation (LOQ)
The limits of detection and quantitation were calculated by the
method based on the standard deviation (r) of responses for
triplicate blank injections of methanol and the slope (S) of
the calibration plot. After that LOD and LOQ were experi-
mentally determined by diluting known concentrations of
ropinirole until the average responses were approximately 3
or 10 times the standard deviation of the responses for tripli-
cate. Now with this the exact value of LOD and LOQ was
determined using the formula given below
LOD ¼ 3:3r=S
LOQ ¼ 10r=S:2.5.3. Accuracy, as recovery
Accuracy was evaluated in triplicate, at three different concen-
trations equivalent by spiking to 50, 100, and 150% of the ac-
tive ingredient, by adding a known amount of ropinirole HCl
standard to a sample of known concentration and calculating
the recovery of ropinirole, RSD (%), and standard error (SE)
for each concentration.
2.5.4. Robustness and ruggedness
The robustness of the method was investigated by making
small deliberate changes in the chromatographic conditions
at four different levels. The chromatographic conditions
selected for deliberate change were, different compositions of
the mobile phase e.g. toluene: ethyl acetate: 6 M ammonia
solution (5:6:0.5, 4.8:5.8:0.5 and 5.2:6.2:0.5 v/v/v), chamber
saturation time (15, 30 and 45 min), plate activation time (1,
2.5 and 5 min) and volume of mobile phase (11.9, 5.95 and
23.8 mL) (Sethi, 1997; Zeaiter et al., 2004). The ruggedness
(Mulholland, 1988) of the method was assessed by comparison
of intra-day and inter-day results for the assay of ropinirole
performed by two analysts in the same laboratory.
2.6. Forced degradation of active pharmaceutical ingredient
To determine whether the method was stability-indicating,
ropinirole tablets and ropinirole active pharmaceutical ingre-
96 G. Mustafa et al.dient (API) powder were stressed under different conditions
to promote degradation. Regulatory guidance in ICH Q2A,
Q2B, Q3B and FDA 21 CFR section 211 requires the devel-
opment and validation of stability-indicating potency assays.
A forced degradation study provides an indication of the
stability-indicating property and speciﬁcity of the proposed
analytical method and was carried out after subjecting ropin-
irole to acid stress (1 N HCl), alkaline stress (1 N NaOH)
hydrolysis, oxidative stress (30% solution of Hydrogen
peroxide), dry heat stress treatment (100 C in laboratory
Oven), photo-degradation stress (UV-chamber) and neutral
hydrolysis stress. In all degradation studies, % recovery of
the drug and impurities after triplicate application
(500 ng spot1) was calculated.
2.6.1. Preparation of acid- and alkali-base induced degradation
product
To 10 mL of aqueous stock solution ropinirole HCl, 10 mL of
2 N NaOH and 2 N HCl were added separately to get the
resultant concentration of 1000 ng/lL. These mixtures were re-
ﬂuxed for 2 h on a water bath at 100 C. The resultant solution
(500 ng spot1) was applied (as per the required volume) on
TLC plate and chromatograms were developed.
2.6.2. Preparation of hydrogen peroxide-induced degradation
product
To 15 mL of aqueous stock solution ropinirole HCl, 15 mL of
hydrogen peroxide (30%, v/v) was added to get the resultant
concentration of 1000 ng/lL. These mixtures were reﬂuxed
for 2 h on a water bath at 100 C. The resultant solution
(500 ng spot1) was applied (as per the required volume) on
TLC plate and the chromatograms were developed.
2.6.3. Photochemical degradation product
The photochemical stability of the drug was also studied by
exposing the stock solution to uv-chamber for 24 h. The resul-
tant solutions were appropriately diluted and 500 ng spot1
was applied (as per the required volume) on TLC plate and
chromatograms were developed.
2.6.4. Dry heat degradation
To study the effect of thermal stress, API powder was exposed
to dry heat (100 C) in a convection oven for 12 h. The samples
were then removed from the oven, and were analyzed after
preparation of 1000 ng lL1 solutions. The resultant solution
(500 ng spot1) was applied (as per the required volume) on
TLC plate and the chromatograms were developed.
2.6.5. Neutral hydrolysis
To 20 mL of aqueous stock solution ropinirole HCl (concen-
tration of 1000 ng/lL) was reﬂuxed for 2 h on a water bath
at 100 C. The resultant solution (500 ng spot1) was applied
(as per the required volume) on a TLC plate and chromato-
grams were developed.
2.7. Kinetic investigation
To study the acidic and alkaline induced degradation kinetics
of ropinirole, accurately weighed 100 mg of drug was dissolved
in 100 mL of methanol (1000 · 103 ng/mL). Ten milliliters(10 mL) of this standard solution was transferred into
200 mL of a double necked round bottomed ﬂask and mixed
properly with 75 mL of 2 N HCl and 2 N NaOH to get a ﬁnal
concentration of 10,000 ngmL1 respectively. These ﬂasks
were reﬂuxed at 313 (40 C), 323 (50 C), 333 (60 C) and
353 K (80 C) temperatures. At deﬁnite time intervals the con-
tents of the ﬂask were quantitatively taken and estimated by
HPTLC method. Each experiment was repeated three times
at each temperature and the time interval and the concentra-
tion of the remaining drug was calculated by spotting a
10 lL sample on a TLC plate. Data were further processed
and different degradation kinetic parameters were calculated.
2.8. Analysis of the marketed formulation
To determine the ropinirole content of tablet formulations,
twenty Ropark tablets (label claim 1 mg) were weighed, to
determine the average weight of the tablets, and then crushed
and mixed using a mortar and pestle. A portion of powder
equivalent to the weight of one tablet was accurately dissolved
in water. Each solution was sonicated for 20 min to achieve
complete dissolution of ropinirole and dilution was done to
get a stock solution of 1000 ng lL1. The resulting solution
was ﬁltered and 0.5 lL (500 ng) solution was applied on
TLC plate followed by development and scanning. The possi-
bility of excipient interference in the analysis was studied.
3. Results and discussion
3.1. Experimental design expert
A three-factorial, Box-Behnken statistical experimental design
was performed using 17 experiments trial run. The indepen-
dent variables and the responses for all 17 optimized trial
experimental runs are given in Table 2. It was observed that
the best-ﬁtted model was the quadratic model and the compar-
ative values of r, sd and % c.v. for the different proposed mod-
els are given in Table 3 along with the regression equation
generated for ﬁnally selected response. Only statistically
signiﬁcant (p< 0.05) Coefﬁcients are included in the equa-
tions. A positive value represents an effect that favors the
optimization, while a negative value indicates an inverse rela-
tionship between the factor and the response (Myers and
Montgomery, 2002). It is clear from the equation that the
factor toluene (X1) as well as ammonia (X3) has a negative ef-
fect and ethyl acetate (X2) has a positive effect on the response
(Y). It also shows that the relationship between responses and
factors is not always linear. Used at different levels in an anal-
ysis or when more than one factor is changed simultaneously, a
factor can produce different degrees of response. Interaction of
X1 and X2 as well as X1 and X3 produce negative impacts on
the response. But the result in case of the square root of differ-
ent factors does not repeat history as shown in its individual
performance. In case of square root of factors X22 and X
2
3 show-
ing positive and X21 giving the negative impact on the response
(Table 3).
The ﬁnal compositional ratios of the mobile phase were se-
lected on the basis of peak resolution and the Rf value using
3D-response surface plot (Fig. 2). The optimized composition
selected was toluene, ethyl acetate and ammonia 5, 6 and 0.5,
respectively for the ﬁnal HPTLC analysis.
Table 3 Summary of results of regression analysis for models and response (Y) Regression equations for the ﬁnally suggested
quadratic model.
Models R2 Adjusted R2 Predicted R2 SD %CV
Linear 0.9783 0.9733 0.9629 0.031 –
2FI 0.9797 0.9676 0.9308 0.034 –
Cubic 0.9994 0.9978 Aliased 0.0089 –
Quadratic 0.9992 0.9983 0.9958 0.0078 1.93
Regression equations of the ﬁtted quadratic model:
Y ¼ 0:38 0:14X1 þ 0:23X2  1:75E 003X3  0:012X1X2  2:5E 003X1X3 þ 7:5E 003X2X3  5:3E 003X21 þ 0:040X22 þ 0:030X23
Figure 2 Response surface plot showing effect of different ratios of toluene (X1), ethyl acetate (X2) and ammonia solution (X3) on
retardation factor (Y).
Figure 3 Chromatogram of standard ropinirole HCl (500 ng
spot1): peak (Rf = 0.58) using optimized mobile phase consisting
Box-Behnken supported validation of stability-indicating high performance 973.2. Method optimization
The TLC procedure was optimized with a view to develop a
stability-indicating assay method to quantify ropinirole HCl
from API as well marketed tablet formulation. Both the pure
drug and the degraded products were spotted as on the TLC
plates and run in optimized solvent system produced by exper-
imental design expert version 7.0.0.1. The mobile phase tolu-
ene–ethyl acetate–6 M ammonia solution (5:6:0.5, v/v/v)
showed good agreement and resolution with area and Rf
(0.58 ± 0.02) for ropinirole HCl. Here ammonia solution
was used to remove the possibility of tailing of peaks as well
to get good resolution from the merging peaks (Fig. 3) after
saturating the chamber for 15 min.
3.3. Calibration curves
The linear regression data for the calibration curves (n= 3) as
shown in Table 4 showed a good linear relationship over the
of toluene–ethyl acetate–6 M ammonia solution (5:6:0.5, v/v/v).
Figure 4 Calibration linearity graph (100–3000 ng spot1) of
ropinirole HCl with Rf at 0.58 ± 0.02, showing the peak linearity.
Table 4 Linear regression data for calibration curve (n= 3).
Linearity range (ng) 100–3000
Regressed equation Y= 8.844x – 22.73
Correlation coeﬃcient 0.9989 ± 0.0052
Slope ± SD 8.8449 ± 0.1057
Conﬁdence limit of slope 8.3898–9.2999
Intercept ± SD 22.734 ± 1.7052
Conﬁdence limit of intercept 15.396–30.071
SE of intercept 0.9845
98 G. Mustafa et al.concentration range of 100–3000 ng spot1 with respect to
area (Fig. 4). No signiﬁcant difference was observed in the
slopes of standard curves.3.4. Validation of the method
3.4.1. Precision
The repeatability of sample application and measurement of
peak area were expressed in terms of relative standard devi-Table 5 Intra- and inter-day precision of HPTLC method (n= 3).
Amount (ng spot1) Intra-day precision
Mean area ± S.D %RSD
250 2296.52 ± 31.69 1.380
500 4444.89 ± 14.29 0.322
1000 8791.03 ± 32.34 0.368
Assay of marketed dosage form
Marketed dosage form
Marketed tablet (Ropark) 4407.04 ± 98.23 0.187
Nanoemulsion (Rop_NE) 3827.13 ± 103.23 0.718
Table 6 Results from recovery studies (n= 3).
Spiking (%) Theoretical claim (ng) % Recov
0 500 99.979
50 750 99.713
100 1000 100.341
150 1250 100.649ation (%RSD) and was found to be very low. The results
depicted in Table 5 revealed intra- and inter-day variation
of ropinirole HCl at three different concentration levels of
250, 500, and 1000 ng spot1. The low %RSD for intra-
day and inter-day assay of ropinirole HCl performed in
the same laboratory, indicating the ruggedness of the
method.3.4.2. Limits of detection (LOD) and quantiﬁcation (LOQ)
In order to estimate the limit of detection (LOD) and limit of
quantiﬁcation (LOQ), blank methanol was spotted thrice and
the sample was run in the solvent system. With the help of
peak area of methanol, SD (34.719) was calculated which
was further used to ﬁnd the exact value of LOD and LOQ.
Limits of detection (LOD) and quantiﬁcation (LOQ) were
found to be 12.95 and 39.25 ng respectively.3.4.3. Recovery studies
By spiking previously analyzed test solution (1000 ng lL1)
with additional standard drug the recovery of the method
was found to be varied from 99.73-100.65%. Values of
recovery (%), RSD (%), and SE are listed in Table 6;
%RSD was always <1% which indicated that the method
is accurate. The intra-day and inter-day variability or preci-
sion data are summarized in Table 5. The low value
(61%) of the RSD is indicative of the repeatability of the
method.3.4.4. Robustness of the method
By introducing small changes in the mobile phase composition,
chamber saturation time, plate activation time, volume of mo-
bile phase and the volume of spot on the plate the effects on
the results were examined (See Section 2.5.4). There were very
slight changes in the peak area, Rf and resolution. The lower
value of SD and %RSD indicate the robustness of method
shown in Table 7.Inter-day precision
SE Mean area ± S.D %RSD SE
18.301 2174.47 ± 36.56 1.681 21.12
8.256 4417.14 ± 24.82 0.562 14.38
18.675 8879.79 ± 45.58 0.513 26.35
%Recovery SE
101.17 4.75
98.73 9.23
ery SD %RSD SE
20.775 0.472 11.995
45.803 0.695 26.445
51.184 0.578 29.552
24.899 0.224 14.376
Figure 5 Chromatogram of ropinirole HCl from marketed tablet (Ropark) showing no any excipients interaction.
Table 7 Robustness of the HPTLC method (n= 3,500 ng spot1).
Parameters S.D %RSD SE Rf
Mobile phase composition (toluene-ethyl acetate-6 M ammonia solution)
(a) 5:6:0.5 (v/v/v) 27.31 0.61 15.77 0.58 ± 0.02
(b) 4.8:5.8:0.5 (v/v/v) 20.11 0.46 11.61 0.59 ± 0.05
(c) 5.2:6.2:0.5 (v/v/v) 58.94 1.37 34.03 0.57 ± 0.08
Mobile phase volume (5.95, 11.9 and 23.8 mL) 13.86 0.32 8.01 0.58 ± 0.04
Chamber saturation time (7.5, 15 and 30 min) 23.89 0.54 13.79 0.59 ± 0.07
Plate activation time (1, 2.5 and 5 min) 12.55 0.28 7.25 0.59 ± 0.07
Applied spot volume (0.5, 1 and 2 lL) 41.38 0.94 23.89 0.57 ± 0.05
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Ropark)
The validated method was used to estimate the ropinirole HCl
content of commercially available brands of the tablet contain-
ing 1 mg ropinirole HCl- Ropark manufactured by Sun
Pharmaceutical Industries, Mumbai, India. Satisfactory results
were obtained. Recovery of ropinirole HCl from Ropark was
100.166% (RSD 0.187%), and the amounts measured were in
good agreement with the label claims. The results of the assay
indicated the method is selective for analysis of ropinirole HCl
without interference from the excipients present (Table 5,
Fig. 5).
3.6. Forced degradation of active pharmaceutical ingredient
The results from the stress testing studies indicated the meth-
od was highly speciﬁc for ropinirole HCl. The degradation
products were completely distinguishable from the parent
compound. No decomposition was detected on exposure of
drug solution to light in a photo stability chamber
(Fig. 6D). The drug was also found stable when exposed
to oxidative stress condition (30% H2O2 solution) as shown
in Fig. 6C.
The drug was found to be unstable in acidic medium. Acidic
stress (1 NHCl) lead to 89.56% recovery with twomajor degra-
dation spots at Rf 3.9 and 2.8 respectively, whereas prominent
peak of ropinirole HCl was stable at Rf 0.58 (Table 8,
Fig. 6A). The drug was found to most unstable under alkalineconditions; the amount decreasing to 64.38% on reﬂuxing the
drug solution with 1 N NaOH for 2 h. Alkaline stress resulted
in four degradation peaks (Fig. 6B) documented in Table 8.
Thermal degradation was done by storing the solid drug
powder in an oven at 100 C for 12 h, giving the recovery
93.03% with two additional degradation peaks (Fig. 6E) at
Rf 0.41 and 0.89 respectively (Table 8). Similarly neutral
hydrolytic stress resulted in approximately 89.05% recovery
of the ropinirole HCl with four degradation peaks (Fig. 6F).
Three degradation products were obtained at Rf 0.38, 0.40,
0.66 and 0.71 respectively (See Table 8). It was not the inten-
tion of the study to identify degradation products, merely to
show that they would not interfere if and when present in
the drug sample.3.7. Degradation kinetics
The kinetics of degradation of ropinirole was investigated in
HCl (2 N) and NaOH (2 N). Each experiment was repeated
three times at each temperature and time interval. The mean
concentration of ropinirole was calculated for each experiment
using 10 lL spot. A decrease in concentration of drug with
increasing stress time was observed. At the selected tempera-
ture (313, 323, 333 and 353 K) the degradation process fol-
lowed ﬁrst-order kinetics (Figs. 7 and 8).
First order rate constant (Kobs), half-life (t1/2) and shelf life
(t0.9) were also calculated from the slope of the straight lines at
each temperature for acidic and alkaline degradation processes
(Table 9).
Figure 6 HPTLC Chromatograms obtained from API degraded by (A) Acidic hydrolysis (1 N HCl), (B) Alkaline hydrolysis (1 N
NaOH), (C) Oxidative stress (30% H2O2), (D) Photodegradation (UV-chamber illuminated with 250 and 365 nm) (E) Dry heat (100 C in
Oven for 12 h) and (F) Neutral hydrolysis.
Table 8 Degradation recovery of ropinirole HCl in different stress conditions.
Stress condition % Recovery (Rf)
Ropinirole HCl DP* 1 DP* 2 DP* 3 DP* 4 DP* 5
Acidic (1 N HCl) 89.56 (0.58) 6.81 (3.9) 4.87 (2.8) – – –
Alkaline (1 M NaOH) 64.38 (0.59) 13.68 (0.15) 10.69 (0.24) – 6.78 (0.68) 6.46 (0.81)
Oxidative (30% H2O2) 99.58 (0.59) – – – – –
Photodegradation (UV-Chamber) 101.22 (0.59) – – – – –
Thermal (100 C in Oven) 93.03 (0.58) 3.23 (0.41) – 5.19 (0.89) – –
Neutral hydrolysis 89.05 (0.59) 2.81 (0.38) 2.91 (0.40) – 3.51 (0.66) 3.88 (0.71)
* DP = Degradation product.
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Data obtained from ﬁrst-order kinetics treatment was fur-
ther subjected to ﬁtting in Arrhenius equation given below:
Here ‘K’ the rate constant; ‘A’ the frequency factor
(kcal mol1); ‘Ea’ the energy of activation (K cal mol
1), R
the gas constant (1.987 kcal1 mol1) and T is the absolute
temperature (K). A plot of (logKobs) values versus the recipro-
cal temperature (1/T · 103), the Arrhenius plot (Fig. 9), was
found to be linear in the selected temperature range (40–
80 C). The energy of activation (Ea; 4.54 · 103 kcal mol1)and degradation rate constant (K25, 4.734 · 103 h1) in alka-
line medium itself supports the susceptibility of the drug over
the acidic stress (Ea; 2.21 · 103 kcal mol1; K25, 7.098 · 10
3 · 103 h1). An extrapolation of Arrhenius plot is used to
calculate the degradation rate constants of alkaline and acidic
degradation processes at room temperature (25 ± 2 C). The
ﬁrst order t1/2 (half life, 97.67 and 146.37 respectively) and
t0.9 (shelf life, 14.87 and 39.11 respectively) were also calcu-
lated for alkaline/acidic stress degradation at 25 C. Data
(Table 10) suggest that the drug is highly susceptible to alka-
line in comparison to acidic stress degradation.
Figure 7 First order plots for degradation of ropinirole in
alkaline stress (NaOH, 2 N) at regulated temperatures.
Figure 8 First order plots for degradation of ropinirole in acidic
stress (HCl, 2 N) at regulated temperatures.
Table 9 Degradation rate constant (Kobs), half life (t1/2), and
shelf life (t0.9) for ropinirole.
Temperature
(Kelvin)
Kobs (h
1) Half life;
t1/2 (h
1)
Shelf life,
t0.9 (h
1)
Alkaline stress (2 N, NaOH)
313 K (40 C) 0.92 · 102 75.23 11.46
323 K (50 C) 1.15 · 102 60.18 9.17
333 K (60 C) 1.61 · 102 42.98 6.55
353 K (80 C) 2.07 · 102 33.43 5.09
Acidic stress (2 N, HCl)
313 K (40 C) 0.29 · 102 231.47 35.27
323 K (50 C) 0.39 · 102 177.01 26.97
333 K (60 C) 0.44 · 102 158.37 24.13
353 K (80 C) 0.46 · 102 150.46 22.93
Figure 9 Arrhenius plots for the degradation of ropinirole in
alkaline stress (NaOH, 2 N) and acidic stress (HCl, 2 N) and its
extrapolation for predicting degradation at room temperature
(25 ± 2 C).
Table 10 Degradation kinetic proﬁle of ropinirole in acidic
and alkaline media at room temperature (25 ± 2 C).
Degradation proﬁle Alkaline
medium
(2 N NaOH)
Acidic
medium
(2 N HCl)
Activation energy, Ea (kcal mol
1) 4.54 · 103 2.21 · 103
Degradation rate constant K25 (h
1) 4.734 · 103 7.098 · 103
Half life, t0.5 (h) 97.67 146.37
Shelf life, t0.9 (h) 14.87 39.11
Arrhenius frequency factor, A
(kcal mol1)
0.0142 0.0086
Box-Behnken supported validation of stability-indicating high performance 1014. Conclusions
A simple, rapid, accurate, and precise HPTLC analytical meth-
od with UV detection has been developed for the determina-
tion of ropinirole HCl in active pharmaceutical ingredient
and in marketed tablet dosage forms. The method was vali-
dated in accordance with ICH guidelines (ICH, 2005). Stress
testing showed that all degradation products were well sepa-
rated from ropinirole HCl, conﬁrming its stability-indicating
capability. The method seems to be suitable for the quality
control in the pharmaceutical industry and also for routine
in vivo study because of its high sensitivity, simplicity, and
selectivity.Acknowledgements
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